Eli Lilly Partners With Prism BioLab In Deal Worth $660M
Pharmaceutical company Eli Lilly and Japanese biotech company Prism BioLab are partnering in a deal worth up to $660 million to discover and develop a new protein-protein interaction target, Prism said...To view the full article, register now.
Already a subscriber? Click here to view full article